Pfizer Inc (PFE)
28 Jul 2014
|Market Cap (Mil.):||$192,377.70|
|Shares Outstanding (Mil.):||6,372.23|
NEW YORK - Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline.
LONDON - AstraZeneca has the chance next week to showcase its financial resilience after resisting a $118 billion takeover bid from Pfizer - and, ironically, it will get a helping hand from its U.S. foe.
(Corrects 10th paragraph to show Pfizer bought Warner Lambert, Pharmacia and Wyeth (not Pfizer)
(Corrects 6th paragraph to show Pfizer's failed bid for AstraZeneca happened in May not June)
ZURICH - Swiss-listed Cosmo Pharmaceuticals said on Wednesday it would merge its Irish subsidiary with U.S. firm Salix Pharmaceuticals , the latest in a wave of overseas deal-making by U.S. companies looking to lower their tax bill.
NEW YORK - Pfizer Inc won the dismissal Tuesday of a long-running shareholder class action accusing the company of misleading investors about the safety of its Celebrex and Bextra pain-relieving drugs.
NEW YORK, July 8 - Pfizer Inc won the dismissal Tuesday of a long-running shareholder class action accusing the company of misleading investors about the safety of its Celebrex and Bextra pain-relieving drugs.
* U.S. drugmaker urges deal in talks with Shire shareholders
* 2nd proposal worth 266 mln stg would involve tax inversion
LONDON - U.S. baby product retailer Destination Maternity will continue its pursuit of Britain's Mothercare after revealing on Wednesday it had two bid proposals rejected.
|Johnson & Johnson (JNJ.N)||$102.11||0.00|
|Novartis AG (NOVN.VX)||CHF79.40||-0.55|
|Merck & Co., Inc. (MRK.N)||$57.97||-0.18|
|Roche Holding Ltd. (ROG.VX)||CHF265.50||-1.50|
|Abbott Laboratories (ABT.N)||$42.93||-0.11|
|Bayer AG (BAYGn.DE)||€99.29||+0.58|
|Bayer AG (BAYE.F)||--||--|
|Sanofi SA (SASY.PA)||€76.33||+0.35|
|AstraZeneca plc (AZN.L)||4,361.00p||-31.00|
|GlaxoSmithKline plc (GSK.L)||1,414.50p||-8.50|
Earnings vs. Estimates
Analyst Research Reports
"The Economy Matters" Report for PFE: the economy's impact on PFE's price and risk, featuring the powerful Economic Climate Rating
Provider: MacroRisk Analytics/EconomicInvestor
Trading Report for (PFE). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
Provider: ValuEngine, Inc.
Provider: Wright Reports
Provider: New Constructs, LLC
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.